C
Clarametyx Biosciences
Unleashing novel biologics to combat life-threatening infections by disrupting bacterial biofilms
About Clarametyx Biosciences
Clarametyx Biosciences is a biotechnology startup that operates in the healthcare sector, specifically in the development of anti-biofilm biologics. Biofilms are groups of microorganisms, such as bacteria, that can cause serious infections and increase antibiotic resistance. Clarametyx's mission is to combat these infections and reduce antibiotic resistance through the use of modern science and innovative strategies.
Read full description
The company's primary clients are likely to be healthcare providers and institutions that deal with patients suffering from bacterial infections. The company's business model revolves around the research, development, and commercialization of its anti-biofilm biologics. It generates revenue through the sale of these biologics to healthcare providers and institutions.
Clarametyx has a strategically focused management team with deep expertise in anti-infective therapeutic and vaccine development. The company recently raised $33 million in Series A financing to advance its biologics for serious bacterial infections. It has also reported positive early Phase 1 safety findings on its immune-enabling antibody therapy, CMTX-101. This therapy is being developed to combat community-acquired bacterial pneumonia, a serious and common infection.
In summary, Clarametyx Biosciences is a promising biotech startup that is leveraging modern science and innovative strategies to combat serious bacterial infections and reduce antibiotic resistance.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Columbus, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 71.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Respiratory, Spinout, Biotech and Pharma, Woman Founder, antibiotic, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jan 2025 | — | — | Kineticos Life Sciences | ↗ |
| SERIES AOther financing | Jan 2024 | $33M | $132M | JobsOhio · Rev1 Ventures · Ohio Innovation Fund · Nationwide Children's Hospital | ↗ |
Growth signals
Latest recorded traffic for Clarametyx Biosciences is 2.4K monthly website visits, up 71.4% over the last three months. Clarametyx Biosciences's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CARB-X
National Institutes of Health
Rev1 Ventures
Series A5 investors entered at this stage
JobsOhio
Ohio Innovation Fund
Nationwide Children's Hospital- CIC Bio Investors
Kineticos Life Sciences
Other known investors1 additional known investor
The Ohio State University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Clarametyx Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clarametyx Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.